FOUNDATION MEDICINE®

Now Available From Foundation Medicine

MMR IHC Testing

Inform immunotherapy eligibility for patients across all solid tumors

With both high-quality CGP and an expanded IHC menu—now including MMR—Foundation Medicine enables you to maximize treatment opportunities for your patients, all through a single order.

VENTANA MMR RxDx PANEL (MLH1, PMS2, MSH2, AND MSH6): FDA-APPROVED CDX INDICATIONS[1]

Indication for use	Therapy	MMR Status
Solid Tumors	JEMPERLI® (dostarlimab-gxly)	Deficient MMR (dMMR)
Solid Tumors	KEYTRUDA® (pembrolizumab)	Deficient MMR (dMMR)
Endometrial Carcinoma	KEYTRUDA® (pembrolizumab) in combination with LENVIMA® (lenvatinib)	Proficient MMR (pMMR)
Endometrial Carcinoma	IMFINZI® (durvalumab)	Deficient MMR (dMMR)

A Simple, Powerful Addition to Your Workflow

Available for order through the Foundation Medicine Online Portal, EMR, or Test Requisition Form (EMR write-ins permitted)

MMR IHC test results will be delivered separately, and then a summary will be added to Foundation Medicine CGP reports when ready

MMR IHC test **turnaround expected to be 3-4 days** from receipt of specimen

Interested in adding MMR IHC to a prior Foundation Medicine test?

Contact your Foundation Medicine Customer Experience Executive or our Client Services team at *888.988.3639* or by email at *client.services@foundationmedicine.com.*

CGP = Comprehensive Genomic Profiling, **MMR** = Mismatch Repair

Reference:

1. https://diagnostics.roche.com/us/en/products/lab/ventana-mmr-rxdx-panel-pid00001002.html

VENTANA MMR RxDx Panel is a qualitative immunohistochemistry test that uses the VENTANA MMR RxDx kit. The VENTANA MMR RxDx panel, using the VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary antibody, VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody, and VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody kits, is intended for laboratory use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6) in formalin-fixed paraffin embedded (FFPE) tissue specimens by light microscopy. VENTANA MMR RxDx Panel is indicated as an aid in identifying patients eligible for treatment with the therapies listed in Table 1 for the indication and MMR status in accordance with the approved therapeutic product labeling. This product is intended for in vitro diagnostic use. For additional information, refer to the VENTANA primary antibody package inserts, #790-5091, #790-5094, #790-5093, and #790-5092. The kit for this test has been approved by the U.S. Food and Drug Administration. Performance characteristics were verified by Foundation Medicine, Inc., per Clinical Laboratory Improvement Amendments (CLIA 88) requirements and in accordance with the College of American Pathologists (CAP). For prescription use only.

FOUNDATION MEDICINE®

www.foundationmedicine.com | Tel 888.988.3639 | Fax 617.418.2290 | US-MMR-2500003 V1.0